Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Spectrum management to meet virtually with B. Riley FBR » 04:55
06/26/20
06/26
04:55
06/26/20
04:55
SPPI

Spectrum

$3.17 /

+0.085 (+2.76%)

Virtual Meetings to be…

Virtual Meetings to be held June 25-26 hosted by B. Riley FBR.

ShowHide Related Items >><<
SPPI Spectrum
$3.17 /

+0.085 (+2.76%)

SPPI Spectrum
$3.17 /

+0.085 (+2.76%)

04/28/20 H.C. Wainwright
Spectrum may have path forward for poziotinib in NSCLC, says H.C. Wainwright
12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
SPPI Spectrum
$3.17 /

+0.085 (+2.76%)

SPPI Spectrum
$3.17 /

+0.085 (+2.76%)

Conference/Events
Spectrum management to meet virtually with B. Riley FBR » 04:55
06/25/20
06/25
04:55
06/25/20
04:55
SPPI

Spectrum

$3.09 /

-0.195 (-5.95%)

Virtual Meetings to be…

Virtual Meetings to be held June 25-26 hosted by B. Riley FBR.

ShowHide Related Items >><<
SPPI Spectrum
$3.09 /

-0.195 (-5.95%)

SPPI Spectrum
$3.09 /

-0.195 (-5.95%)

04/28/20 H.C. Wainwright
Spectrum may have path forward for poziotinib in NSCLC, says H.C. Wainwright
12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
SPPI Spectrum
$3.09 /

-0.195 (-5.95%)

SPPI Spectrum
$3.09 /

-0.195 (-5.95%)

Conference/Events
Spectrum management to meet virtually with B. Riley FBR » 10:04
06/23/20
06/23
10:04
06/23/20
10:04
SPPI

Spectrum

$3.38 /

+0.06 (+1.81%)

Virtual Meetings to be…

Virtual Meetings to be held June 25-26 hosted by B. Riley FBR.

ShowHide Related Items >><<
SPPI Spectrum
$3.38 /

+0.06 (+1.81%)

SPPI Spectrum
$3.38 /

+0.06 (+1.81%)

04/28/20 H.C. Wainwright
Spectrum may have path forward for poziotinib in NSCLC, says H.C. Wainwright
12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
SPPI Spectrum
$3.38 /

+0.06 (+1.81%)

SPPI Spectrum
$3.38 /

+0.06 (+1.81%)

Over a month ago
Earnings
Spectrum reports Q1 EPS (22c), consensus (35c) » 16:03
05/07/20
05/07
16:03
05/07/20
16:03
SPPI

Spectrum

$2.87 /

+ (+0.00%)

"The progress in our…

"The progress in our development pipeline speaks to the investigator interest and the commitment of our team during these unprecedented times," said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. "The PDUFA date for ROLONTIS remains October 24, 2020 and our updated poziotinib strategy is well under way. We continue to drive the business forward and remain focused on achieving our milestones this year."

ShowHide Related Items >><<
SPPI Spectrum
$2.87 /

+ (+0.00%)

04/28/20 H.C. Wainwright
Spectrum may have path forward for poziotinib in NSCLC, says H.C. Wainwright
12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
Hot Stocks
Spectrum initiates same day dosing clinical trial for ROLONTIS » 07:27
04/30/20
04/30
07:27
04/30/20
07:27
SPPI

Spectrum

$2.97 /

+0.09 (+3.13%)

Spectrum Pharmaceuticals…

Spectrum Pharmaceuticals announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as chemotherapy. The trial will evaluate the duration of severe neutropenia when administered at three different time points on the same day following standard chemotherapy in patients with early stage breast cancer. ROLONTIS is an investigational drug not approved by the FDA and the BLA is currently under active review by the agency for the treatment of chemotherapy induced neutropenia with a PDUFA date of October 24.

ShowHide Related Items >><<
SPPI Spectrum
$2.97 /

+0.09 (+3.13%)

04/28/20 H.C. Wainwright
Spectrum may have path forward for poziotinib in NSCLC, says H.C. Wainwright
12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
Recommendations
Spectrum may have path forward for poziotinib in NSCLC, says H.C. Wainwright » 12:24
04/28/20
04/28
12:24
04/28/20
12:24
SPPI

Spectrum

$2.99 /

+0.08 (+2.75%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White noted that Spectrum Pharmaceuticals announced additional data during the American Association for Cancer Research Virtual Annual Meeting from its Phase 2 ZENITH20 trial's Cohort 1 evaluating poziotinib in patients with previously treated non-small cell lung cancer with EGFR exon 20 mutations. White believes the Cohort 1 data clearly show clinical activity, but that the company requires a different strategy to show clinical benefit, he tells investors. The analyst, who sees a possible path forward for poziotinib, reiterates his Buy rating and $11 price target on Spectrum shares.

ShowHide Related Items >><<
SPPI Spectrum
$2.99 /

+0.08 (+2.75%)

12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
12/26/19 Cantor Fitzgerald
Spectrum downgraded to Neutral from Overweight at Cantor Fitzgerald
Hot Stocks
Spectrum amends ZENITH20 trial, announces strategy update for poziotinib program » 07:28
04/28/20
04/28
07:28
04/28/20
07:28
SPPI

Spectrum

$2.91 /

+0.015 (+0.52%)

Spectrum provided an…

Spectrum provided an update on its ZENITH20 Phase 2 clinical trial evaluating poziotinib in non-small cell lung cancer, or NSCLC, patients with EGFR and HER2 exon 20 insertion mutations. The protocol has been amended to explore additional twice daily dosing regimens as well as lower single daily dosage amounts. Earlier use of corticosteroids has also been added to the protocol in an effort to help patients better tolerate poziotinib and stay on therapy for a longer time. Previously announced results for Cohort 1 of the SPECTRUM20 trial were presented during the oral plenary of the Lung Cancer Targeted Therapy session at the American Association for Cancer Research. Although the results for Cohort 1 did not meet the primary endpoint, as previously announced, poziotinib demonstrated a positive treatment effect with a 68.7% disease control rate. Cohort 1 of the ZENITH20 trial enrolled 115 patients who received 16 mg/day of poziotinib. The intent-to-treat analysis showed that 17 patients had a response and 62 patients had stable disease for a 68.7% disease control rate, or DCR. The confirmed objective response rate, or ORR, was 14.8%. Based on the FDA reviewed protocol, an observed ORR of 30%, with 17% as the lower bound for 95% CI was considered to be the clinically meaningful efficacy in the study. The median duration of response was 7.4 months with progression free survival of 4.2 months. The safety profile was in-line with the type of adverse events seen with other second-generation EGFR tyrosine kinase inhibitors. Approximately 63% of patients experienced a grade 3 or 4 adverse event, the most common of which was rash and diarrhea. Tolerability may have led to reduced drug exposure as 68% of patients were dose reduced and 88% of patients had a temporary drug/dosing interruption. The median relative dose intensity was 72%. The high incidence of dose reductions and interruptions may indicate that the once daily starting dose of 16 mg was high and the resulting reduced dose intensity could have impaired the efficacy results. The company believes that a reduction in dose interruptions and daily dosing could lead to a greater number of deeper and more durable responses. Cohort 5 is evaluating patients using a range of different doses compared to Cohort 1. Patients are randomized to 10, 12 or 16 mg administered once daily, and with the amended protocol, the trial will also explore 6 and 8 mg administered twice daily. Cohorts 4, 6 and 7 have also been amended to use 8 mg twice daily dosing. The ZENITH20 trial is made up of seven independent cohorts. Cohorts 1-4 are each independently powered for a pre-specified statistical hypothesis with a primary endpoint of ORR. Cohorts 5 - 7 are exploratory studies. Cohort 3 is now fully enrolled and the company expects to report results for Cohort 2 in mid-2020 and Cohort 3 by the end of the year.

ShowHide Related Items >><<
SPPI Spectrum
$2.91 /

+0.015 (+0.52%)

12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
12/26/19 Cantor Fitzgerald
Spectrum downgraded to Neutral from Overweight at Cantor Fitzgerald
Over a quarter ago
Syndicate
Spectrum files $150M mixed securities shelf  16:19
03/20/20
03/20
16:19
03/20/20
16:19
SPPI

Spectrum

$2.30 /

+0.03 (+1.32%)

 
ShowHide Related Items >><<
SPPI Spectrum
$2.30 /

+0.03 (+1.32%)

12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
12/26/19 Cantor Fitzgerald
Spectrum downgraded to Neutral from Overweight at Cantor Fitzgerald
Conference/Events
Spectrum to host conference call » 07:55
03/18/20
03/18
07:55
03/18/20
07:55
SPPI

Spectrum

$2.11 /

+0.03 (+1.44%)

Conference call to review…

Conference call to review data from the Phase 2 Clinical Trial for Poziotinib will be held on March 18 at 8 am. Webcast Link

ShowHide Related Items >><<
SPPI Spectrum
$2.11 /

+0.03 (+1.44%)

12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
12/26/19 Cantor Fitzgerald
Spectrum downgraded to Neutral from Overweight at Cantor Fitzgerald
Conference/Events
Spectrum to host conference call » 04:55
03/18/20
03/18
04:55
03/18/20
04:55
SPPI

Spectrum

$2.11 /

+0.03 (+1.44%)

Conference call to review…

Conference call to review data from the Phase 2 Clinical Trial for Poziotinib will be held on March 18 at 8 am. Webcast Link

ShowHide Related Items >><<
SPPI Spectrum
$2.11 /

+0.03 (+1.44%)

12/27/19 B. Riley FBR
Spectrum price target lowered to $11 from $18 at B. Riley FBR
12/26/19 Guggenheim
Spectrum downgraded to Neutral from Buy at Guggenheim
12/26/19
Spectrum price target lowered to $11 from $41 at H.C. Wainwright
12/26/19 Cantor Fitzgerald
Spectrum downgraded to Neutral from Overweight at Cantor Fitzgerald

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.